LHYFE SAS (LHYFE.PA) Fundamental Analysis & Valuation

EPA:LHYFE • FR0014009YQ1

2.48 EUR
-0.04 (-1.59%)
Last: Mar 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This LHYFE.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LHYFE. LHYFE was compared to 83 industry peers in the Oil, Gas & Consumable Fuels industry. LHYFE may be in some trouble as it scores bad on both profitability and health. LHYFE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. LHYFE.PA Profitability Analysis

1.1 Basic Checks

  • LHYFE had negative earnings in the past year.
  • LHYFE had a negative operating cash flow in the past year.
  • LHYFE had negative earnings in each of the past 5 years.
  • LHYFE had a negative operating cash flow in each of the past 5 years.
LHYFE.PA Yearly Net Income VS EBIT VS OCF VS FCFLHYFE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • LHYFE's Return On Assets of -15.49% is on the low side compared to the rest of the industry. LHYFE is outperformed by 92.77% of its industry peers.
  • LHYFE has a Return On Equity of -72.30%. This is amonst the worse of the industry: LHYFE underperforms 93.98% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -72.3%
ROIC N/A
ROA(3y)-14.91%
ROA(5y)-15.02%
ROE(3y)-30.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LHYFE.PA Yearly ROA, ROE, ROICLHYFE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • LHYFE has a better Gross Margin (80.73%) than 85.54% of its industry peers.
  • LHYFE's Gross Margin has improved in the last couple of years.
  • LHYFE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y97.82%
GM growth 5YN/A
LHYFE.PA Yearly Profit, Operating, Gross MarginsLHYFE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. LHYFE.PA Health Analysis

2.1 Basic Checks

  • LHYFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LHYFE has about the same amount of shares outstanding.
  • Compared to 5 years ago, LHYFE has more shares outstanding
  • The debt/assets ratio for LHYFE is higher compared to a year ago.
LHYFE.PA Yearly Shares OutstandingLHYFE.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
LHYFE.PA Yearly Total Debt VS Total AssetsLHYFE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -0.54, we must say that LHYFE is in the distress zone and has some risk of bankruptcy.
  • LHYFE's Altman-Z score of -0.54 is on the low side compared to the rest of the industry. LHYFE is outperformed by 86.75% of its industry peers.
  • LHYFE has a Debt/Equity ratio of 1.55. This is a high value indicating a heavy dependency on external financing.
  • LHYFE's Debt to Equity ratio of 1.55 is on the low side compared to the rest of the industry. LHYFE is outperformed by 84.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF N/A
Altman-Z -0.54
ROIC/WACCN/A
WACC7.4%
LHYFE.PA Yearly LT Debt VS Equity VS FCFLHYFE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • LHYFE has a Current Ratio of 1.69. This is a normal value and indicates that LHYFE is financially healthy and should not expect problems in meeting its short term obligations.
  • LHYFE has a better Current ratio (1.69) than 74.70% of its industry peers.
  • A Quick Ratio of 1.68 indicates that LHYFE should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.68, LHYFE belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.68
LHYFE.PA Yearly Current Assets VS Current LiabilitesLHYFE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. LHYFE.PA Growth Analysis

3.1 Past

  • The earnings per share for LHYFE have decreased strongly by -16.15% in the last year.
  • LHYFE shows a strong growth in Revenue. In the last year, the Revenue has grown by 209.99%.
  • LHYFE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 195.81% yearly.
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.16%
Revenue 1Y (TTM)209.99%
Revenue growth 3Y195.81%
Revenue growth 5YN/A
Sales Q2Q%177.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.93% on average over the next years. This is quite good.
  • LHYFE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 129.95% yearly.
EPS Next Y6.25%
EPS Next 2Y12.15%
EPS Next 3Y12.93%
EPS Next 5YN/A
Revenue Next Year111.33%
Revenue Next 2Y104.13%
Revenue Next 3Y130.16%
Revenue Next 5Y129.95%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LHYFE.PA Yearly Revenue VS EstimatesLHYFE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LHYFE.PA Yearly EPS VS EstimatesLHYFE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. LHYFE.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • LHYFE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LHYFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LHYFE.PA Price Earnings VS Forward Price EarningsLHYFE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LHYFE.PA Per share dataLHYFE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LHYFE's earnings are expected to grow with 12.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.15%
EPS Next 3Y12.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LHYFE.PA Dividend Analysis

5.1 Amount

  • LHYFE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LHYFE.PA Fundamentals: All Metrics, Ratios and Statistics

LHYFE SAS

EPA:LHYFE (3/11/2026, 7:00:00 PM)

2.48

-0.04 (-1.59%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)02-03
Earnings (Next)03-31
Inst Owners8.62%
Inst Owner ChangeN/A
Ins Owners21.29%
Ins Owner ChangeN/A
Market Cap119.31M
Revenue(TTM)8.07M
Net Income(TTM)-36.79M
Analysts84
Price Target4.08 (64.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)12.2%
EPS NY rev (3m)11.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.79
P/FCF N/A
P/OCF N/A
P/B 2.34
P/tB 3.95
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.17
BVpS1.06
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -72.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.73%
FCFM N/A
ROA(3y)-14.91%
ROA(5y)-15.02%
ROE(3y)-30.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y97.82%
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 483.84%
Cap/Sales 391.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.68
Altman-Z -0.54
F-Score5
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)957.78%
Cap/Depr(5y)2682.27%
Cap/Sales(3y)1925.18%
Cap/Sales(5y)13341.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.16%
EPS Next Y6.25%
EPS Next 2Y12.15%
EPS Next 3Y12.93%
EPS Next 5YN/A
Revenue 1Y (TTM)209.99%
Revenue growth 3Y195.81%
Revenue growth 5YN/A
Sales Q2Q%177.45%
Revenue Next Year111.33%
Revenue Next 2Y104.13%
Revenue Next 3Y130.16%
Revenue Next 5Y129.95%
EBIT growth 1Y-10.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.8%
EBIT Next 3Y24.02%
EBIT Next 5Y27.12%
FCF growth 1Y-65.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.71%
OCF growth 3YN/A
OCF growth 5YN/A

LHYFE SAS / LHYFE.PA FAQ

Can you provide the ChartMill fundamental rating for LHYFE SAS?

ChartMill assigns a fundamental rating of 2 / 10 to LHYFE.PA.


What is the valuation status of LHYFE SAS (LHYFE.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to LHYFE SAS (LHYFE.PA). This can be considered as Overvalued.


What is the profitability of LHYFE stock?

LHYFE SAS (LHYFE.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for LHYFE stock?

The financial health rating of LHYFE SAS (LHYFE.PA) is 2 / 10.